» Articles » PMID: 27313781

TERT Core Promotor Mutations in Early-Onset Bladder Cancer

Overview
Journal J Cancer
Specialty Oncology
Date 2016 Jun 18
PMID 27313781
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Activating mutations in the core promoter of the TERT gene have been described in many different tumor entities. In vitro models showed a two- to fourfold increase in transcriptional activity of the TERT promoter through creation of a consensus binding motif for Ets/TCF transcription factors caused by these mutations. TERT core promoter mutations are the most common mutations in bladder cancer with a frequency between 55.6% and 82.8% described so far, and are independent of stage and grade. Since limited data on molecular alterations of early-onset bladder tumors exists, we assessed the frequency of TERT core promoter mutations in early-onset bladder cancer. Two cohorts of bladder tumors (early-onset patient group; n=144 (age of onset of disease ≤45 years); unselected, consecutive group; n=125) were examined for TERT core promoter mutations. After microdissection and extraction of DNA the corresponding hotspot regions in the TERT core promoter were examined by Sanger-sequencing or a SNaPshot approach. A significantly lower frequency of TERT core promoter mutations was found in tumors from the early-onset cohort compared to the consecutive cohort (57.6% vs. 84.8%, p<0.001). Among the early-onset cohort cases younger than the cohort's median age of 39 years at disease onset showed a significantly reduced number of TERT promoter mutations (31/67, 46,3%) than cases aged between 39 and 45 years (52/77, 67.5%; p=0.012). This association was not found in the consecutive cases. Mutation status was independent of tumor stage and grade. We conclude that in tumors from early-onset bladder cancer patients TERT core promoter mutations are not as frequent as in bladder tumors from consecutive cases, but seem to play an important role there as well. In patients below 39 years of age TERT core promoter mutations are a more infrequent event, suggesting different mechanisms of tumorigenesis in these young patients.

Citing Articles

Telomerase Reverse Transcriptase-Promoter Mutation in Young Patients with Bladder Tumors.

Perez Gonzalez S, Heredia-Soto V, Giron de Francisco M, Perez-Fernandez E, Casans-Frances R, Mendiola Sabio M Curr Issues Mol Biol. 2024; 46(4):2845-2855.

PMID: 38666908 PMC: 11049539. DOI: 10.3390/cimb46040178.


NAB2::STAT6 fusions and genome-wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors.

Eschbacher K, Tran Q, Moskalev E, Jenkins S, Fritchie K, Stoehr R Brain Pathol. 2024; 34(6):e13256.

PMID: 38523251 PMC: 11483515. DOI: 10.1111/bpa.13256.


Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis.

Shuai H, Duan X, Zhou J, Liu Y, Wu T BMC Urol. 2023; 23(1):177.

PMID: 37915019 PMC: 10621162. DOI: 10.1186/s12894-023-01349-9.


Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.

Mohanty S, Lobo A, Mishra S, Cheng L J Pers Med. 2023; 13(5).

PMID: 37240925 PMC: 10222089. DOI: 10.3390/jpm13050756.


The impact of genetic variants in the gene on bladder cancer susceptibility.

Qu W, Zhang F, Cheng Y, Li J, Zhou J Front Endocrinol (Lausanne). 2022; 13:989030.

PMID: 36246885 PMC: 9554954. DOI: 10.3389/fendo.2022.989030.


References
1.
Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J . The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2013; 33(42):4978-84. DOI: 10.1038/onc.2013.446. View

2.
Vinagre J, Pinto V, Celestino R, Reis M, Populo H, Boaventura P . Telomerase promoter mutations in cancer: an emerging molecular biomarker?. Virchows Arch. 2014; 465(2):119-33. DOI: 10.1007/s00428-014-1608-4. View

3.
Comperat E, Larre S, Roupret M, Neuzillet Y, Pignot G, Quintens H . Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015; 466(5):589-94. DOI: 10.1007/s00428-015-1739-2. View

4.
Kinde I, Munari E, Faraj S, Hruban R, Schoenberg M, Bivalacqua T . TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res. 2013; 73(24):7162-7. PMC: 3966102. DOI: 10.1158/0008-5472.CAN-13-2498. View

5.
Wild P, Giedl J, Stoehr R, Junker K, Boehm S, van Oers J . Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger. J Pathol. 2006; 211(1):18-25. DOI: 10.1002/path.2075. View